BTK and mantle cell lymphoma: Although ibrutinib has transformed the treatment of R/R MCL, there are still several limitations when used as a single agent, including a low CR rate, short PFS, and development of resistance due to mutations of BTK or other molecular targets in the B‐cell receptor pathway.15